PT918772E - Sais di-hidrato de mesilato de 5-(2-[4-(1,2-benzisotiazol-3-il)-1-piperazinil]-6-cloro-1,3-di-hidro-2(1h)-indol-2-ona (=ziprasidona), sua preparacao e sua utilizacao como antagonistas de dopamina d2 - Google Patents

Sais di-hidrato de mesilato de 5-(2-[4-(1,2-benzisotiazol-3-il)-1-piperazinil]-6-cloro-1,3-di-hidro-2(1h)-indol-2-ona (=ziprasidona), sua preparacao e sua utilizacao como antagonistas de dopamina d2

Info

Publication number
PT918772E
PT918772E PT97914520T PT97914520T PT918772E PT 918772 E PT918772 E PT 918772E PT 97914520 T PT97914520 T PT 97914520T PT 97914520 T PT97914520 T PT 97914520T PT 918772 E PT918772 E PT 918772E
Authority
PT
Portugal
Prior art keywords
benzisoyzazol
ziprasidone
ona
indol
dopamine
Prior art date
Application number
PT97914520T
Other languages
English (en)
Portuguese (pt)
Inventor
Frank Robert Busch
Carol Anne Rose
Russell James Shine
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT918772E publication Critical patent/PT918772E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
PT97914520T 1996-05-07 1997-04-10 Sais di-hidrato de mesilato de 5-(2-[4-(1,2-benzisotiazol-3-il)-1-piperazinil]-6-cloro-1,3-di-hidro-2(1h)-indol-2-ona (=ziprasidona), sua preparacao e sua utilizacao como antagonistas de dopamina d2 PT918772E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
PT918772E true PT918772E (pt) 2004-12-31

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97914520T PT918772E (pt) 1996-05-07 1997-04-10 Sais di-hidrato de mesilato de 5-(2-[4-(1,2-benzisotiazol-3-il)-1-piperazinil]-6-cloro-1,3-di-hidro-2(1h)-indol-2-ona (=ziprasidona), sua preparacao e sua utilizacao como antagonistas de dopamina d2

Country Status (40)

Country Link
US (1) US6245765B1 (OSRAM)
EP (1) EP0918772B1 (OSRAM)
JP (1) JP3494659B2 (OSRAM)
KR (1) KR100333215B1 (OSRAM)
CN (1) CN1091769C (OSRAM)
AP (1) AP765A (OSRAM)
AR (1) AR007004A1 (OSRAM)
AT (1) ATE278689T1 (OSRAM)
AU (1) AU731267B2 (OSRAM)
BG (1) BG63544B1 (OSRAM)
BR (1) BR9709889A (OSRAM)
CA (1) CA2252898C (OSRAM)
CO (1) CO4940466A1 (OSRAM)
CZ (1) CZ289215B6 (OSRAM)
DE (1) DE69731094T2 (OSRAM)
DK (1) DK0918772T3 (OSRAM)
DZ (1) DZ2222A1 (OSRAM)
EA (1) EA001190B1 (OSRAM)
EG (1) EG24076A (OSRAM)
ES (1) ES2229342T3 (OSRAM)
GT (1) GT199700052A (OSRAM)
HR (1) HRP970236B1 (OSRAM)
ID (1) ID16867A (OSRAM)
IL (1) IL126591A (OSRAM)
IS (1) IS2080B (OSRAM)
MA (1) MA24171A1 (OSRAM)
MY (1) MY119997A (OSRAM)
NO (1) NO312514B1 (OSRAM)
NZ (1) NZ332218A (OSRAM)
OA (1) OA10909A (OSRAM)
PL (1) PL188330B1 (OSRAM)
PT (1) PT918772E (OSRAM)
SI (1) SI0918772T1 (OSRAM)
SK (1) SK282837B6 (OSRAM)
TN (1) TNSN97074A1 (OSRAM)
TR (1) TR199802240T2 (OSRAM)
TW (1) TW491847B (OSRAM)
UA (1) UA46840C2 (OSRAM)
WO (1) WO1997042191A1 (OSRAM)
ZA (1) ZA973876B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
CZ20023860A3 (cs) * 2000-06-02 2004-01-14 Pfizer Products Inc. S-Methyldihydroziprasidon pro léčení psychických a očních poruch
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
MXPA05012317A (es) * 2003-05-16 2006-01-30 Pfizer Prod Inc Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas.
KR20080022595A (ko) 2003-06-03 2008-03-11 테바 파마슈티컬 인더스트리즈 리미티드 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
EP1827374B1 (en) * 2004-11-16 2014-11-05 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
EP1742943A1 (en) * 2005-02-11 2007-01-17 Teva Pharmaceutical Industries Ltd Process of preparing ziprasidone mesylate
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
AU2008254957A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
CA2727573A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
CN107595771A (zh) * 2010-10-18 2018-01-19 大日本住友制药株式会社 注射用缓释制剂
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DK0904273T3 (da) 1996-05-07 2003-07-07 Pfizer Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist

Also Published As

Publication number Publication date
ID16867A (id) 1997-11-20
BG102892A (en) 1999-09-30
BG63544B1 (bg) 2002-04-30
GT199700052A (es) 2001-08-29
CZ349398A3 (cs) 1999-09-15
BR9709889A (pt) 1999-08-10
TW491847B (en) 2002-06-21
EG24076A (en) 2008-05-11
NZ332218A (en) 2005-02-25
TNSN97074A1 (fr) 2005-03-15
AP9700976A0 (en) 1997-07-31
HRP970236B1 (en) 2002-12-31
HK1017892A1 (en) 1999-12-03
NO312514B1 (no) 2002-05-21
AU2174797A (en) 1997-11-26
PL329884A1 (en) 1999-04-12
HRP970236A2 (en) 1998-06-30
IL126591A (en) 2001-11-25
PL188330B1 (pl) 2005-01-31
CN1216991A (zh) 1999-05-19
CA2252898C (en) 2003-04-08
OA10909A (en) 2001-10-26
IL126591A0 (en) 1999-08-17
KR20000010824A (ko) 2000-02-25
IS4874A (is) 1998-10-20
DZ2222A1 (fr) 2002-12-03
MY119997A (en) 2005-08-30
ES2229342T3 (es) 2005-04-16
CA2252898A1 (en) 1997-11-13
AP765A (en) 1999-09-17
CO4940466A1 (es) 2000-07-24
US6245765B1 (en) 2001-06-12
JPH11509867A (ja) 1999-08-31
IS2080B (is) 2006-02-15
EA001190B1 (ru) 2000-12-25
MA24171A1 (fr) 1997-12-31
AU731267B2 (en) 2001-03-29
DK0918772T3 (da) 2005-01-10
ATE278689T1 (de) 2004-10-15
KR100333215B1 (ko) 2002-06-20
SK282837B6 (sk) 2002-12-03
CZ289215B6 (cs) 2001-12-12
SI0918772T1 (en) 2005-02-28
DE69731094D1 (de) 2004-11-11
TR199802240T2 (OSRAM) 1999-02-22
DE69731094T2 (de) 2006-02-23
EA199800912A1 (ru) 1999-04-29
JP3494659B2 (ja) 2004-02-09
ZA973876B (en) 1998-11-06
NO985194D0 (no) 1998-11-06
EP0918772A1 (en) 1999-06-02
UA46840C2 (uk) 2002-06-17
SK150898A3 (en) 2000-02-14
WO1997042191A1 (en) 1997-11-13
EP0918772B1 (en) 2004-10-06
NO985194L (no) 1998-11-06
CN1091769C (zh) 2002-10-02
AR007004A1 (es) 1999-10-13

Similar Documents

Publication Publication Date Title
PT918772E (pt) Sais di-hidrato de mesilato de 5-(2-[4-(1,2-benzisotiazol-3-il)-1-piperazinil]-6-cloro-1,3-di-hidro-2(1h)-indol-2-ona (=ziprasidona), sua preparacao e sua utilizacao como antagonistas de dopamina d2
PT904273E (pt) Sal tri-hidrato de mesilato de 5-{2-¬4-(1,2-benzisotiazol-3-il)-1-piperazinil|-etil}-6-cloro-1,3-di-hidro-2h-indol-2-ona(=ziprasidona) sua preparacao e sua utilizacao como antagonista de dopamina d2
FI956279L (fi) Menetelmiä ja välituotteita 5-/2-(4-(bentsoisotiatsol-3-yyli)piperatsin-1-yyli)etyyli/-6-kloori-1,3-dihydroindol-2-onin valmistamiseksi
AR028281A1 (es) Derivados de 2-(arilalquilamino) pirimidona y derivados de 2-(heteroaroarilalquilamino) pirimidona
AP9901696A0 (en) Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl)amino) ehtoxy benzyl)thiazolidine-2,4-dione
AU2002343036A1 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amido)ethoxy)benzyl)thiazolidine-2,4-dione and pharmaceutical compositions comprising the same
DE69714024D1 (de) 4-(benzo-1,3-dioxolyl)-pyrrolidin-3-carbonsaure-derivate als endothelin-antagonisten
ATE525362T1 (de) 2-(3-(4-(2-t-butyl-6-trifluormethylpyrimidin-4-
MA25908A1 (fr) Chlorhydrate de 5-(4(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) benzyl)thiazolidine-2,4-dione.
PL354991A1 (en) Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate and use thereof as endothelin antagonist
PL376721A1 (pl) Pochodne acylowe 5-(2-(4-(1,2-benzoizotiazol-3-ilo)-1-piperazynylo) etylo)-6-chloro-1,3-dihydro-2H-indol-2-onu o działaniu neuroleptycznym
HUP9902404A3 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-choloro-1,3-dihydro-2(2h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
NO20021986D0 (no) Natrium-2-(4,6-dimetyl-pyrimidin-2-yloksy)-3-(2-(3,4- dimetoksyfenyl)etoksy)-3,3-difenylpropionat og anvendelse deravsom endothelin-antagonist
SI1556378T1 (sl) Acilni derivati 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperaznil)etil)-6-kloro-1,3-dihidro -2H-indol-2-ona z nevrolepticno aktivnostjo